PT  - JOURNAL ARTICLE
AU  - Chelsea M. Blankenship
AU  - Lisa L. Hunter
AU  - M. Patrick Feeney
AU  - Madison Cox
AU  - Lindsey Bittinger
AU  - Angie Garinis
AU  - Li Lin
AU  - Gary McPhail
AU  - John P. Clancy
TI  - Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in Cystic Fibrosis
AID  - 10.1101/2020.04.29.20084848
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.29.20084848
4099  - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20084848.short
4100  - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20084848.full
AB  - Purpose The purpose of this study is to better understand the prevalence of ototoxicity-related hearing loss and its functional impact on communication in a pediatric and young adult cohort with cystic fibrosis (CF) and individuals without CF (controls).Method Observational, cross-sectional investigation of hearing function in children, teens, and young adults with CF (n = 57, mean = 15.0 yr.) who received intravenous aminoglycoside antibiotics and age- and gender-matched controls (n = 61, mean = 14.6 yr.). Participants completed standard and extended high frequency audiometry, middle ear measures, speech perception tests, and a hearing and balance questionnaire.Results Individuals with CF were 3 to 4 times more likely to report issues with hearing, balance, and tinnitus and performed significantly poorer on speech perception tasks compared to controls. A higher prevalence of hearing loss was observed in individuals with CF (57%) compared to controls (37%). CF and control groups had similar proportions of slight and mild hearing losses, however individuals with CF were 7.6 times more likely to have moderate and greater degrees of hearing loss. Older participants displayed higher average EHF thresholds, with no effect of age on average SF thresholds. Although middle ear dysfunction has not previously been reported to be more prevalent in CF, this study showed that 16% had conductive or mixed hearing loss and higher rates of previous otitis media and pressure equalization (PE) tube surgeries compared to controls.Conclusions Individuals with CF have a higher prevalence of conductive, mixed and sensorineural hearing loss, poorer speech-in-noise performance and higher rates of multiple symptoms associated with otologic disorders (tinnitus, hearing difficulty, dizziness, imbalance and otitis media) compared to controls. Accordingly, children with CF should be asked about these symptoms, receive baseline hearing assessment(s) prior to treatment with potentially ototoxic medications, and at regular intervals thereafter in order to provide otologic and audiologic treatment for hearing and ear-related problems to improve communication functioning.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the National Institute Health, National Institute on Deafness and Other Communication Disorders Grant R01DC010202 (multi-principal investigators: Doug Keefe, Lisa L. Hunter and Patrick Feeney), National Institute of Health, Clinical and Translational Science Award Program Grant 5UL1TR001425-04 (Center for Clinical and Translational Science Training at the University of Cincinnati) and the Cincinnati Children’s Hospital Medical Center Research Foundation Place Outcomes Research Award (multi-principle investigators: Lisa L. Hunter and John P. Clancy).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.ACAir-ConductionAGAminoglycosideBKB-SINBamford-Kowal-Bench Speech-in-NoiseBCBone-conductionCCHMCCincinnati Children’s Hospital Medical CenterCHLConductive Hearing LossCFCystic FibrosisEHFExtended High FrequencyIV-AGIntravenous-AminoglycosideMHLMixed Hearing LossNormal HearingNHPressure EqualizationPESignal-to-Noise RatioSNRSensitive (Frequency) Range for OtotoxicitySROSensorineural Hearing LossSNHLSpeech Reception ThresholdSRTStandard FrequencySF